You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Exact Sciences discussed new Cologuard data; Danaher reviewed Cepheid's 2020 performance; and NanoString talked about forthcoming spatial biology products.
Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.
Last year, the company processed more than 1 million tests, most of them for its reproductive health business, but interest in Prospera and Signatera is growing.
Hologic said the acquisition of Biotheranostics will give it a company that operates in markets that are adjacent and complementary to its own.
Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.
The company anticipates total revenues of $3.9 billion for 2020, including $1 billion from its COVID-19-related business.
The Wall Street Journal reports that the company launched by Amazon, Berkshire Hathaway, and JPMorgan Chase to transform healthcare is closing.
Originally, the company had said it was planning to offer $250 million worth of shares in the offering, which is expected to close Dec. 7.
Included in the offering — Twist Bioscience's third this year — are 75,000 shares of common stock offered by certain selling shareholders.
In their first conference call with investors, PacBio's new CEO and CFO laid out a strategic plan for the company as it weathers the COVID-19 pandemic.
The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.
The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.
In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.
President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.